CytoDyn Inc. (CYDY) Scheduled to Present at The MicroCap Conference on October 1
- CytoDyn will present on October 1 at 9 a.m. EST (6 a.m. PST) at The Microcap Conference at the Essex House in New York City, with live webcast available
- CYDY is a biotechnology company developing humanized monoclonal antibodies for the treatment of multiple therapeutic indications, such as HIV, tumor metastasis and graft-vs-host disease
CytoDyn Inc. (OTCQB: CYDY) management is set to present at The Microcap Conference on October 1 at the Essex House in New York at 9 a.m. EST (http://nnw.fm/o9AgA). The MicroCap presentation will be available on live webcast, and a replay will be hosted on the investor’s section of the company’s website at http://ir.CytoDyn.com.
CYDY is in advanced clinical development with PRO 140, a leading monoclonal antibody for the treatment and prevention of HIV, which offers potential both in combination with other HIV treatments and as single-agent therapy. PRO 140 is a humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor that plays multiple roles with implications in HIV infection, tumor metastasis and immune signaling.
In the setting of HIV/AIDS, PRO 140 belongs to a new class of therapeutics called viral-entry inhibitors; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. At the same time, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 plays a central role in tumor invasion and metastasis and that expression of CCR5 is an indicator of disease status in several cancers. Moreover, researchers have shown that drugs that block CCR5 can block tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. In human pilot trials, CCR5 inhibition has been shown to remarkably limit colon cancer metastasis. CytoDyn is conducting additional research with PRO 140 in the cancer setting and plans to initiate Phase 2 human clinical trials when appropriate.
The CCR5 receptor also plays a central role in modulating immune cell trafficking to sites of inflammation, and it is crucial for the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others have shown that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with PRO 140 to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to PRO 140 for the prevention of graft-versus-host disease (GvHD).
For more information, visit the company’s website at www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- CytoDyn will present on October 1 at 9 a.m. EST (6 a.m. PST) at The Microcap Conference at the Essex House in New York City, with live webcast available
- CYDY is a biotechnology company developing humanized monoclonal antibodies for the treatment of multiple therapeutic indications, such as HIV, tumor metastasis and graft-vs-host disease
CytoDyn Inc. (OTCQB: CYDY) management is set to present at The Microcap Conference on October 1 at the Essex House in New York at 9 a.m. EST (http://nnw.fm/o9AgA). The MicroCap presentation will be available on live webcast, and a replay will be hosted on the investor’s section of the company’s website at http://ir.CytoDyn.com.
CYDY is in advanced clinical development with PRO 140, a leading monoclonal antibody for the treatment and prevention of HIV, which offers potential both in combination with other HIV treatments and as single-agent therapy. PRO 140 is a humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor that plays multiple roles with implications in HIV infection, tumor metastasis and immune signaling.
In the setting of HIV/AIDS, PRO 140 belongs to a new class of therapeutics called viral-entry inhibitors; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. At the same time, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 plays a central role in tumor invasion and metastasis and that expression of CCR5 is an indicator of disease status in several cancers. Moreover, researchers have shown that drugs that block CCR5 can block tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. In human pilot trials, CCR5 inhibition has been shown to remarkably limit colon cancer metastasis. CytoDyn is conducting additional research with PRO 140 in the cancer setting and plans to initiate Phase 2 human clinical trials when appropriate.
The CCR5 receptor also plays a central role in modulating immune cell trafficking to sites of inflammation, and it is crucial for the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others have shown that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with PRO 140 to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to PRO 140 for the prevention of graft-versus-host disease (GvHD).
For more information, visit the company’s website at www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
